UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma model

Leukemia, 2012-06, Vol.26 (6), p.1436-1439

2012

Volltextzugriff (PDF)

Tracing leachates at waste sites using geophysical and geochemical modelling

Environmental earth sciences, 2006-03, Vol.49 (5), p.720-732

2006

Volltextzugriff (PDF)

Taming the cancer cell

Journal of internal medicine, 2014-07, Vol.276 (1), p.2-4

2014

Volltextzugriff (PDF)

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy

Cancer gene therapy, 2013-07, Vol.20 (7), p.386-393

2013

Volltextzugriff (PDF)

Taming the cancer cell: Introduction

Journal of internal medicine, 2014-07, Vol.276 (1), p.2

2014

Volltextzugriff (PDF)

SUMO‐modified insulin‐like growth factor 1 receptor (IGF‐1R) increases cell cycle progression and cell proliferation

Journal of cellular physiology, 2017-10, Vol.232 (10), p.2722-2730

2017

Volltextzugriff (PDF)

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy

Cancer gene therapy, 2013-12, Vol.20 (12), p.702

2013

Volltextzugriff (PDF)

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions

Oncotarget, 2017-02, Vol.8 (6), p.10213-10224

2017

Volltextzugriff (PDF)

Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells

Blood, 1992-01, Vol.79 (2), p.495-502

1992

Volltextzugriff (PDF)

Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia

The Journal of experimental medicine, 2015-06, Vol.212 (6), p.833-843

2015

Volltextzugriff (PDF)

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target

Oncotarget, 2016-02, Vol.7 (6), p.6809-6823

2016

Volltextzugriff (PDF)

One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies

Epigenomes, 2021-10, Vol.5 (4), p.22

2021

Volltextzugriff (PDF)

Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9

Biochemical and biophysical research communications, 2011-01, Vol.404 (2), p.667-671

2011

Volltextzugriff (PDF)

Polycomb target genes are silenced in multiple myeloma

PloS one, 2010-07, Vol.5 (7), p.e11483

2010

Volltextzugriff (PDF)

P01-24 The combination of the IGF-1 receptor inhibitor picropodophylin (PPP) and the BH3 mimetic ABT-737 has synergistic anti-myeloma activity

Growth hormone & IGF research, 2012-10, Vol.22, p.S40-S40

2012

Volltextzugriff (PDF)

The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia

Leukemia, 2006-01, Vol.20 (1), p.77-81

2006

Volltextzugriff (PDF)

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

Oncotarget, 2017-11, Vol.8 (61), p.103731-103743

2017

Volltextzugriff (PDF)

Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model

Cancer research (Chicago, Ill.), 2012-10, Vol.72 (20), p.5348-5362

2012

Volltextzugriff (PDF)

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells

Blood, 2006-01, Vol.107 (2), p.669-678

2006

Volltextzugriff (PDF)

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone

Blood, 2004-04, Vol.103 (8), p.3138-3147

2004

Volltextzugriff (PDF)

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model

Blood, 2006-01, Vol.107 (2), p.655-660

2006

Volltextzugriff (PDF)

Targeting the IGF‐1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival

International journal of cancer, 2007-10, Vol.121 (8), p.1857-1861

2007

Volltextzugriff (PDF)

IL-6 as a growth factor for human multiple myeloma cells--a short overview

Current topics in microbiology and immunology, 1990, Vol.166, p.3

1990

Volltextzugriff (PDF)

An Epigenomic Map of Multiple Myeloma Reveals the Importance of Polycomb Gene Silencing for the Malignancy

BLOOD, 2014-12, Vol.124 (21), p.2192-2192

2014

Volltextzugriff (PDF)

1 – 25 von 291

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(279)
Mit Volltextzugriff
(260)

Publikationsform

Sprache

Englisch
(291)
Schwedisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

European Heart Journal
(25)
Blood
(19)
International Journal Of Cardiology
(10)
Journal Of Internal Medicine
(9)
European Journal Of Heart Failure
(8)
The Lancet
(7)
International Journal Of Cancer
(5)
Leukemia
(5)
Oncotarget
(5)
Plos One
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma model

Tracing leachates at waste sites using geophysical and geochemical modelling

Taming the cancer cell

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy

Taming the cancer cell: Introduction

SUMO‐modified insulin‐like growth factor 1 receptor (IGF‐1R) increases cell cycle progression and cell proliferation

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions

Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells

Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia

Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target

One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies

Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9

Polycomb target genes are silenced in multiple myeloma

P01-24 The combination of the IGF-1 receptor inhibitor picropodophylin (PPP) and the BH3 mimetic ABT-737 has synergistic anti-myeloma activity

The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model

Targeting the IGF‐1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival

IL-6 as a growth factor for human multiple myeloma cells--a short overview

An Epigenomic Map of Multiple Myeloma Reveals the Importance of Polycomb Gene Silencing for the Malignancy

Suchergebnisse filtern